-
-
Description
Naturally occurring nucleoside that slows conduction through AV node
-
Mechanism of Action
Decreases conduction of electrical impulses by binding up phosphate and preventing the formation of ATP within the cardiac cells. Essentially interrupting the AV impulse reentry pathways in PSVT
-
Onset if Action
- Onset-20-30seconds
- Peak- 20-30seconds
- Duration- 30seconds
- Half-life- 10seconds
-
Indications
Used in SVT refractory to common vagal maneuvers (symptomatic SVT)
-
Contraindications
- 2nd or 3rd degree heart block
- Sick sinus syndrome
- Know hypersensitivity to the drug
-
Precautions/Side effects
- Causes dysthymias
- Caution w/ Asthma pts
- Facial flushing, headache, shortness of breath, chest pain, dizziness, nausea
-
Adult dose
6mg IV Bolus. Followed by saline flush. If not corrected in 1-2 min 12mg IV Bolus. If not corrected in 1-2 min 12mg IV Bolus
-
Pedi dose
- 0.1mg/kg 1st dose
- 0.2mg/kg 2nd and 3rd dose
-
-
-
-
Route of administration
IV/IO
-
How supplied
Pre-filled syringes and 6-12mg vials
|
|